Head to Head Review: Green Cures & Botanical Distribution (OTCMKTS:GRCU) versus Becton, Dickinson and Company (NYSE:BDX)

Green Cures & Botanical Distribution (OTCMKTS:GRCU) and Becton, Dickinson and Company (NYSE:BDX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Green Cures & Botanical Distribution and Becton, Dickinson and Company, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Green Cures & Botanical Distribution	0	0	0	0	0.00
Becton, Dickinson and Company	0	9	3	0	2.25

Becton, Dickinson and Company has a consensus target price of $205.40, indicating a potential upside of 8.64%. Given Becton, Dickinson and Company’s stronger consensus rating and higher probable upside, analysts plainly believe Becton, Dickinson and Company is more favorable than Green Cures & Botanical Distribution.

Volatility & Risk

Green Cures & Botanical Distribution has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.

Profitability

This table compares Green Cures & Botanical Distribution and Becton, Dickinson and Company’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Green Cures & Botanical Distribution	N/A	N/A	N/A
Becton, Dickinson and Company	7.51%	16.23%	7.46%

Institutional & Insider Ownership

87.0% of Becton, Dickinson and Company shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Green Cures & Botanical Distribution and Becton, Dickinson and Company”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Green Cures & Botanical Distribution	N/A	N/A	N/A	N/A	N/A
Becton, Dickinson and Company	$20.18 billion	2.69	$1.71 billion	$5.56	34.00

Becton, Dickinson and Company has higher revenue and earnings than Green Cures & Botanical Distribution.

Summary

Becton, Dickinson and Company beats Green Cures & Botanical Distribution on 9 of the 10 factors compared between the two stocks.

About Green Cures & Botanical Distribution

Global Roundtable Corporation operates in the health and wellness business. It also provides products and ancillary services in the mental wellness segment and optical-vision medical care. The company was formerly known as Green Cures & Botanical Distribution Inc. and changed its name to Global Roundtable Corporation in May 2023. Global Roundtable Corporation was incorporated in 1986 and is based in Denver, Colorado.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.